RBC Capital analyst Gregory Renza upgraded Verrica Pharmaceuticals to Outperform from Sector Perform with a price target of $11, up from $4.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on VRCA:
- Verrica Pharmaceuticals Announces Resubmission of New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum
- Verrica Pharmaceuticals resubmits NDA for VP-102 in molluscum contagiosum
- Verrica Pharmaceuticals announces technology transfer to Piramal Pharma
- Verrica Pharmaceuticals Announces the Successful Technology Transfer of Bulk Solution Manufacturing of VP-102 to Piramal Pharma Solutions